Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 11/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.52 |
| ▸ | AKT1 | P31749 | 2/20 | 0.45 |
| ▸ | AKT2 | P31751 | 2/20 | 0.45 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10041273 | 0.92 | PDE4B (0.46) | PDE4BPDE4DAKT1AKT2AKT3 | |
| SCHEMBL14124485 | 0.77 | AKT1 (0.46) | PDE4BPDE4DAKT1AKT2AKT3 | |
| SCHEMBL10041258 | 0.76 | MAPK1 (0.49) | MEN1POLBKMT2A | |
| SCHEMBL10041264 | 0.76 | BACE1 (0.35) | PDE4BPDE4DMEN1KMT2A | |
| SCHEMBL12724785 | 0.76 | RAB9A (0.43) | PDE4BPDE4DAKT1AKT2AKT3 | |
| SCHEMBL19072663 | 0.72 | PDE4B (0.82) | PDE4BPDE4D | |
| SCHEMBL13052922 | 0.72 | PDE10A (0.56) | PDE4BAKT1AKT2RXFP1TP53 | |
| SCHEMBL10041268 | 0.72 | RPS6KA5 (0.41) | TP53POLB | |
| SCHEMBL10041270 | 0.72 | AOC3 (0.39) | — | |
| SCHEMBL13916710 | 0.71 | PDE4B (0.55) | PDE4BPDE4DAKT1AKT2AKT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8147987-B2 | Organic electroluminescent element and compounds for use in the element | FUJIFILM CORPORATION (JP) | 2012-04-03 | — | — | US | disclosed |
| US-8147987-B2 | Organic electroluminescent element and compounds for use in the element | FUJIFILM CORPORATION (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20070202357-A1 | Organic electroluminescent element and compounds for use in the element | FUJIFILM CORPORATION (JP) | 2007-08-30 | — | — | US | disclosed |
| US-20070202357-A1 | Organic electroluminescent element and compounds for use in the element | FUJIFILM CORPORATION (JP) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070202357-A1 | Organic electroluminescent element and compounds for use in the element | RPL31, RPL38, RPL39 | PDE4B 4561/4885PDE4D 4813/4885AKT1 3723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.